pharmaphorum

SEPTEMBER 29, 2022

A digital patient monitoring tool developed by UK company CyberLiver has been given a breakthrough designation by the FDA for out-of-hospital management of patients with cirrhosis at risk of complications. The post Digital tool cuts hospital readmissions in cirrhosis patients appeared first on.

Patients 52

Patients Management Consulting FDA 52

World of DTC Marketing

DECEMBER 22, 2020

81 percent of American adults have a smartphone, according to Pew Research but we must remember there is a huge difference between “health (wellness) apps and apps that focus on specific health conditions” The global mHealth app market is growing fast and expected to reach $111 billion by 2025. Sleep monitoring.

Pharma 230

Pharma Doctors Patients Management 230

Penrod

JANUARY 12, 2024

Additionally, OCR specifies that when a healthcare entity subject to HIPAA collects such information, like when a potential patient seeks services in their area, that data is classified as Protected Health Information (PHI). The post Patient Privacy in 2024 appeared first on Penrod.

Patients 52

Patients Healthcare Provider Healthcare Healthcare 52

European Pharmaceutical Review

MAY 22, 2024

Sandoz stated that it anticipates the biosimilars to launch in Europe from November 2025 at the earliest. This medicine is also authorised as a treatment for bone loss associated with hormone ablation in males diagnosed with prostate cancer, who have a greater risk of fractures.

Medicine 71

Medicine Healthcare Healthcare Patients 71

European Pharmaceutical Review

FEBRUARY 2, 2024

So construction of the new radioligand therapy manufacturing site in France is a major step towards making these promising new treatments available to cancer patients with high unmet needs.

Manufacturing 83

Manufacturing Distribution Leads Pharmaceutical 83

European Pharmaceutical Review

NOVEMBER 21, 2023

According to GSK, thirty-five million patients with respiratory conditions globally relying on its metered dose inhaler. Dosing of first patients is planned in the first half of 2024. However, this accounts for nearly half of GSK’s carbon footprint, and contributes to the carbon footprint of global health systems.

Manufacturing 106

Manufacturing Patients Pharma Leads 106

European Pharmaceutical Review

FEBRUARY 27, 2024

The new facility, known as Amgen Ohio, “was designed with the latest innovation and technology to deliver safe, reliable medicines for ‘every patient, every time,'” stated Robert Bradway, Chairman and Chief Executive Officer at Amgen. It is the company ’s most advanced manufacturing facility to date.

Manufacturing 97

Manufacturing Food and Drug Administration Food Networking 97

World of DTC Marketing

JULY 17, 2022

Novo Nordisk more than doubled its sales targets for obesity drugs to $3.7bn by 2025. It has to persuade patients to sign up for some heinous side effects. When patients stop taking Wegovy, their appetite returns within weeks, and they pack on weight. Its share price has risen 26 percent in the past year.

Side effects 209

Side effects Insurance Doctors Prescription 209

pharmaphorum

OCTOBER 6, 2022

Fresh with a new brand identity, the France-headquartered pharma group has pledged to grow its oncology sales from its current objective of €1 billion in 2025 to €3 billion in 2030, continuing a diversification of its business from its traditional focus on cardiovascular diseases. billion and $1.8 billion, respectively, five years later.

Sales 79

Sales Pharma Government Medicine 79

European Pharmaceutical Review

AUGUST 1, 2022

The joint Big Data Steering Group of the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) has published a third workplan, setting actions to be delivered by 2025. According to EMA, the new plan will further enhance the efficient integration of data analysis into the regulatory evaluation of medicinal products.

Medicine 88

Medicine Networking Electronics Healthcare 88

Pharmaceutical Technology

MAY 19, 2023

The US Food and Drug Administration (FDA) has approved AbbVie’s Rinvoq (upadacitinib) for patients with Crohn’s disease who do not respond to TNF blockers, a common immune suppressant treatment for the condition. Data from two Phase III studies, U-EXCEED and U-EXCEL, involving 857 patients was used to support the approval.

Food and Drug Administration 105

Food and Drug Administration FDA Sales Food 105

European Pharmaceutical Review

JUNE 9, 2023

“We are pleased to extend the strategic collaboration with Pfizer as we share and support their strong vision to bring innovative solutions for patients around the globe,” said Mike McDermott, Chief Global Supply Officer, Executive Vice President, Pfizer, commenting on the biosimilars manufacturing deal.

Manufacturing 91

Manufacturing Patients Management Pharmaceutical 91

European Pharmaceutical Review

NOVEMBER 2, 2023

He added that the approval of Wezlana “could have a meaningful impact for patients managing their disease.” Stelara biosimilars in the US market The first Stelara biosimilars are expected to enter the US market in 2025. “We

Food and Drug Administration 86

Food and Drug Administration FDA Side effects Safety 86

pharmaphorum

SEPTEMBER 9, 2022

It also marks the first move by Kry beyond the primary care category, where it provides virtual GP consultation services to millions of patients across various European countries, into tools for the treatment and prevention of chronic diseases. billion in 2025. Novo Nordisk recently predicted its obesity sales could reach $3.7

Pharmacology 85

Pharmacology Patients Management Consulting 85

European Pharmaceutical Review

NOVEMBER 10, 2023

The construction projects will be finalised from the end of 2025 through to 2029. This important investment will ensure the continuous development of our late-phase pipeline into deliveries of important medicines for treatments to patients worldwide”, Wulff declared in the original annoucement.

Manufacturing 93

Manufacturing Pharmaceutical manufacturing Pharmaceutical Medicine 93

Pharmaceutical Technology

JUNE 7, 2023

of patients’ body weight (52lb or 24kg) and greater than 50% of patients taking Mounjaro achieving at least 20% body weight reductions. Lilly’s blockbuster therapy to tackle the global obesity pandemic will undoubtedly gain widespread adoption by patients and providers.

Leads 98

Leads Marketing FDA Sales 98

European Pharmaceutical Review

APRIL 18, 2023

It is estimated that 28 million patients suffer from chronic cough, with 10 million patients globally and six million in the US and European Union (EU) suffering from RCC for over a year, according to a 2015 study. Data is anticipated in H2 2024 and 2025, respectively. per share in cash.

Biopharma 79

Biopharma Sales Patients Medical 79

Pharma Leaders

MARCH 29, 2023

The European Medicines Agency (EMA) reported “remarkable” progress despite the pandemic in a mid-point assessment of its “Regulatory Science Strategy to 2025” to build a more adaptive regulatory system that will encourage innovation — including advances in clinical trials and a new real-world data (RWD) network.

Networking 52

Networking Medicine Patients 52

pharmaphorum

JULY 21, 2022

The PD-1 inhibitor missed the mark in the phase 3 KEYNOTE-412 trial in 780 newly-diagnosed patients with head and neck squamous cell carcinoma (HNSCC), a notoriously hard-to-treat form of cancer. The post Bid to expand Keytruda use in head and neck cancer therapy fails appeared first on.

Patients 98

Patients 98

pharmaphorum

SEPTEMBER 21, 2022

The European Commission has followed the lead of the US FDA and approved AstraZeneca’s Tezspire as an add-on maintenance therapy for patients with severe asthma, becoming the first and only biologic that can be used in all patients, and not restricted to those with specific forms of the disease. billion or more. billion or more.

Sales 101

Sales Biopharma Medicine Patients 101

pharmaphorum

OCTOBER 26, 2022

The drug was highlighted at Boehringer’s R&D update earlier this year as one of the most promising candidates among 15 new medicines it plans to bring to market by 2025, fuelled by a €25 billion R&D spend. The programme will include two trials – FIBRONEER IPF and FIBRONEER-ILD – which will recruit patients across 40 countries.

Recruitment 87

Recruitment Prospecting Marketing Patients 87

Penrod

JANUARY 19, 2024

This bill became effective on January 17th, 2025, which means healthcare providers operating in the state of New Jersey need to make sure they comply with the law or face severe penalties. These providers are expected to undertake extensive privacy and security measures to safeguard patients’ information.

Healthcare Provider 52

Healthcare Provider Healthcare Healthcare Patients 52

European Pharmaceutical Review

OCTOBER 6, 2023

For example: higher patient compliance, easier administration and greater convenience. A potential regulatory approval for the combination vaccine is targeted for 2025. There are several benefits of the combination vaccine as a preventative measure against these respiratory conditions, according to the pharmaceutical company.

Safety 94

Safety Pharmaceutical Manufacturing Patients 94

Pharmaceutical Technology

SEPTEMBER 5, 2022

Until 2025, we have strong growth ahead of us, but we also believe we can continue to grow very strongly post-2025 and it’s all about innovation in the pipeline.”. On 23 August, at a Reuters Newsmakers online forum, Soriot announced his interest in increasing AstraZeneca’s portfolio of bolt-on acquisitions leading up to 2025.

FDA 114

FDA Pharmaceutical Biopharma Pharma 114

European Pharmaceutical Review

NOVEMBER 23, 2022

The European Medicines Agency (EMA) has established the Quality Innovation Expert Group (QIG) to aid innovative approaches for the development, manufacture and quality control (QC) of medicines, including new technologies, digitalisation, novel materials and novel devices for patients in the European Union (EU).

Medicine 97

Medicine Networking Manufacturing Training 97

Pharmaceutical Technology

JUNE 4, 2023

Early-stage non-small cell lung cancer (NSCLC) is typically treated with surgery followed by adjuvant therapy (chemo ± radiation) in patients deemed to be at higher risk. A subgroup analysis showed that patients with PD-L1 expression levels higher than 1% derived more benefit from Keytruda treatment. in the Keytruda arm, versus 40.6%

Distribution 75

Distribution Recruitment Patients Marketing 75

pharmaphorum

OCTOBER 4, 2022

The life sciences company Solid Biosciences is merging with the privately-held gene therapy company AavantiBio in a deal which is expected to result in a combined sum of $215 million in cash and investments – projected to be enough for funding into 2025.

Management 94

Management Manufacturing Patients Medicine 94

European Pharmaceutical Review

FEBRUARY 17, 2023

Dr Sartor noted that there is increasing evidence that targeted alpha therapies for prostate cancer is effective even for “patients who progress on or after lutetium-based PSMA therapies.” The Phase II trial is expected to evaluate approximately 100 patients with four treatment cycles per patient occurring every eight weeks.

Patients 74

Patients Safety Pharmaceutical Medical 74

PM360

OCTOBER 25, 2023

According to a report by McKinsey & Company, the medical affairs function is on track to rise in importance, becoming the third strategic pillar alongside the research and development (R&D) and commercial functions by 2025. Regulatory concerns. A slip here can result in legal issues and harm the company’s reputation.

Management 105

Management Medical Pharma Pharmaceutical 105

Pharmaceutical Technology

APRIL 17, 2023

The proposed merger is expected to realise at least $50m of net transaction cash proceeds, set to be used to finance the merged entity’s business as well as Phase II trials and operations through the second quarter of 2025. The merger is scheduled to be completed by the third quarter of 2023.

Patients 98

Patients Leads Pharmaceutical Marketing 98

Pharmaceutical Technology

DECEMBER 21, 2022

The vaccine manufacturing facility will also offer National Health Service (NHS) patients access to the company’s Covid-19 vaccines that can provide protection against various variants. Planned to be operational by 2025, the construction of the facility is anticipated to begin early next year.

Government 140

Government Manufacturing Pharmaceutical Marketing 140

Pharmaceutical Technology

JANUARY 19, 2023

While allogeneic hematopoietic stem cell transplants (HSCT) provide long-term benefit to a subset of AML patients, other cell therapy modalities such as natural killer (NK) cells or chimeric antigen receptor (CAR)-T cells have failed to show conclusive benefit in late-stage clinical trials.

Marketing 52

Marketing FDA Sales Management 52

European Pharmaceutical Review

NOVEMBER 23, 2023

The Oligonucleotide Manufacturing Innovation Centre of Excellence will also facilitate “a highly skilled workforce” to be trained and development to accelerate access of these medicines to patients, CPI noted. CPI confirmed that the centre will establish operations during 2024 and be finished in late 2025.

Manufacturing 81

Manufacturing Medicine Government Pharmaceutical 81

pharmaphorum

DECEMBER 22, 2022

The Parma site is due to become operational from 2024, with FDA, IFA, and EMA approvals due to be sought for 2025. In brief, the European plan for Chiesi is in-house drug development of biologicals and rare disease targeting.

Manufacturing 77

Manufacturing FDA Patients 77

Pharmaceutical Technology

MAY 25, 2023

The Medicines and Healthcare products Regulatory Agency (MHRA) aims to launch a pilot genetic biobank that will gather patient data to associate drug-related adverse events to their genetic makeup. This would ideally allow doctors to use rapid genomic screening tests that can help them to select the safest potential treatment for a patient.

Side effects 52

Side effects Medicine Recruitment Doctors 52

European Pharmaceutical Review

SEPTEMBER 7, 2022

establishing a multi-stakeholder platform to facilitate the evolution of the clinical trials environment through regular dialogue between all stakeholders, including patients, healthcare professionals and academia. implementing the CTR – focus on CTIS and CTR training activities and trouble-shooting any issues encountered by trial sponsors.

Medicine 94

Medicine Training Networking Pharmaceutical 94

Medgadget

SEPTEMBER 29, 2023

This layer of specialized endothelium significantly restricts which drug molecules can enter the brain, normally greatly limiting treatment options for patients with brain-based disease. In addition, it isn’t sustainable to have patients in-hospital for months at a time seeking this type of treatment.

Medicine 106

Medicine Distribution Specialization Medical 106